T4

T4 (also known as LEU-001) is an autologous, second-generation chimeric antigen receptor T-cell (CAR-T) therapy developed by King's College London in collaboration with Guy's and St Thomas' NHS Foundation Trust and Leucid Bio. It is designed for the treatment of locally advanced or recurrent head and neck squamous cell carcinoma (HNSCC). The therapy consists of patient-derived T-cells engineered via retroviral transduction to co-express a pan-ErbB-specific CAR called T1E28ζ and an IL-4-responsive chimeric cytokine receptor (4αβ). The T1E28ζ CAR targets the ErbB family of receptor dimers (pan-ErbB), which are frequently upregulated in HNSCC, while the 4αβ receptor enables selective enrichment and expansion of the transduced cells using IL-4 during manufacturing. To mitigate the risk of on-target, off-tumor toxicity due to low-level ErbB expression in healthy tissues, T4 is administered intratumorally. A Phase 1 clinical trial (NCT01818323) has been completed, demonstrating a favorable safety profile and preliminary efficacy, with disease stabilization observed in 60% of patients.

Other names

T4 immunotherapyT-4 immunotherapyT 4 immunotherapyT4 CAR-TT-4 CAR-TT 4 CAR-TT4 CAR-T cell therapyT-4 CAR-T cell therapyT 4 CAR-T cell therapyT4 CAR-T therapyT-4 CAR-T therapyT 4 CAR-T therapy